OctreoPharm Sciences GmbH is a Berlin-based biopharmaceutical company focused on developing novel radiopharmaceuticals for neuroendocrine tumours. Its lead product is the diagnostic radiopharmaceutical SOMscan(R), intended for detection and treatment control of neuroendocrine tumours. The company closed a €5m financing round to fund the clinical development of SOMscan(R). Clinical trials up to Phase II are expected to be implemented within the next two years. If these trials succeed, OctreoPharm expects to seek European approval in 2014 following an additional financing round, with U.S. approval to follow thereafter. The company is led by founders Dr. Hakim Bouterfa (Managing Director, responsible for clinical development) and Udo Blaseg (Managing Director).

Total raised

$7M

Funding rounds

1

Latest round

Equity

Latest activity

Apr 2011